Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has reported Phase 1 data and outlined plans for an adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody designed to prevent Lyme disease. The company expects to initiate the Phase 2 trial in the first half of 2027, pending agreement with the U.S. Food and Drug Administration. TNX-4800 targets Borrelia burgdorferi, the bacterium responsible for Lyme disease, and is engineered to provide extended protection during tick season, a feature that could address significant gaps in current prevention strategies.
The candidate was licensed from UMass Chan Medical School and represents a novel approach to Lyme disease prophylaxis. Unlike traditional vaccines that rely on stimulating the immune system to produce antibodies, TNX-4800 is a direct antibody therapy that may offer immediate and sustained protection. Currently, there are no approved prophylactic options for Lyme disease in the United States, underscoring the potential importance of this development. According to the company, TNX-4800's long-acting formulation could simplify dosing and improve adherence, particularly during peak tick activity months.
Tonix Pharmaceuticals is a fully integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. Its flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8 mg), was recently approved as the first new treatment for fibromyalgia in over 15 years. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. Beyond Lyme disease, Tonix is advancing a pipeline of immunology programs, including TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
The announcement of TNX-4800's progress comes at a time when Lyme disease incidence is rising, with an estimated 476,000 Americans diagnosed and treated each year, according to the Centers for Disease Control and Prevention. If successful, TNX-4800 could provide a new tool for at-risk populations, such as outdoor workers and residents of endemic areas. The company's planned Phase 2 study will evaluate the candidate's efficacy in preventing infection, building on the Phase 1 data that supported its safety and pharmacokinetic profile.
Investors and stakeholders can find the latest news and updates regarding Tonix Pharmaceuticals in the company's newsroom at https://ibn.fm/TNXP. The full press release detailing the Phase 1 data and Phase 2 plans is available at https://ibn.fm/yB2M8.
